UTHR Q1 2025 Earnings — United Therapeutics Corporation Revenue & Financial Results | Market Cap Arena

UTHRUnited Therapeutics Corporation

$24B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$794M+17.2% YoY

Gross Profit

$702M88.4% margin

Operating Income

$383M48.2% margin

Net Income

$322M40.6% margin

EPS (Diluted)

$6.63

QoQ Revenue Growth

+7.9%

Cash Flow

Operating Cash Flow

$461M

Free Cash Flow

$386M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$7.7B

Total Liabilities

$937M

Stockholders' Equity

$6.8B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$794M	$678M	+17.2%
Gross Profit	$702M	$605M	+16.1%
Operating Income	$383M	$356M	+7.4%
Net Income	$322M	$307M	+5.1%

Revenue Segments

Tyvaso

$466M59%

Remodulin

$138M17%

Orenitram

$121M15%

Unituxin

$58M7%

Adcirca

$6M1%

Product and Service, Other

$5M1%

Geographic Segments

UNITED STATES

$750M94%

Non-US

$45M6%